CUMULATIVE SUPPLEMENT 03
March 2010



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2010

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

Cumulative Supplement 03

March 2010

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

CUMULATIVE SUPPLEMENT 03
March 2010

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASCENT PEDIATRICS INC (ASCENT PEDS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
GOLDLINE LABORATORIES INC (GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
HLR TECHNOLOGY (HLR)	HOFFMANN LA ROCHE INC (HOFFMANN LA ROCHE)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
MEDICIS PHARMACEUTICAL CORP (MEDICIS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)

PROCTER AND GAMBLE CO PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)
SCIELE PHARMA INC (SCIELE PHARMA INC)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE LABORATORIES INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2009	MAR 2010	JUN 2010	SEPT 2010	DEC 2010
DRUG PRODUCTS LISTED	13065	13216			
SINGLE SOURCE	2460 (18.8%)	2474 (18.7%)			
MULTISOURCE	10516 (80.5%)	10653 (80.6%)			
THERAPEUTICALLY EQUIVALENT	10367 (79.3%)	10502 (79.5%)			
NOT THERAPEUTICALLY EQUIVALENT	149 (1.1%)	151 (1.1%)			
EXCEPTIONS[1]	89 (0.7%)	89 (0.7%)			
NEW MOLECULAR ENTITIES APPROVED	3	5			
NUMBER OF APPLICANTS	718	727			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application

number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AA		MIKART	325MG;50MG	A089987	001	Oct 26, 1992	Feb	CTEC

PHRENILIN

AA	+	VALEANT	325MG;50MG	A087811	001	Jun 19, 1985	Feb	CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+	NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009	Feb	CRLD
AA		WEST WARD	500MG;50MG;40MG	A040261	001	Oct 28, 1998	Feb	CTEC

ESGIC-PLUS

AA	+	MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996	Feb	CTEC

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		CONCORD LABS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Feb	CTEC
AA			500MG;50MG;40MG	A040883	001	Dec 23, 2008	Feb	CTEC
AA		MALLINCKRODT	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Feb	CTEC
AA		MIKART	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Feb	CTEC
AA		VINTAGE PHARMS	325MG;50MG;40MG	A040511	001	Aug 27, 2003	Feb	CTEC
AA			500MG;50MG;40MG	A040513	001	Aug 25, 2003	Feb	CTEC
AA		WATSON LABS	500MG;50MG;40MG	A040267	001	Jul 30, 1998	Feb	CTEC
AA		WEST WARD	325MG;50MG;40MG	A089718	001	Jun 12, 1995	Feb	CTEC
AA			500MG;50MG;40MG	A040336	001	Aug 18, 1999	Feb	CTEC

ESGIC-PLUS

AA	+	MIKART	500MG;50MG;40MG	A089451	001	May 23, 1988	Feb	CTEC

FIORICET

AA	+	WATSON PHARMS	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb	CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	+	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010	Feb	NEWA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

AB	+	WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000	Feb	CRLD

TALACEN

		@ SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982	Feb	DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

		STIEFEL LABS INC	17.5MG	N019821	003	Aug 06, 2009	Jan	NEWA
			22.5MG	N019821	004	Aug 06, 2009	Jan	NEWA

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>		@ MYLAN	200MG	A074727	001	Apr 22, 1997	Mar	CMFD
>A>	AB		200MG	A074727	001	Apr 22, 1997	Mar	CMFD

TABLET; ORAL
ACYCLOVIR

>D>		@ MYLAN	400MG	A075211	001	Sep 28, 1998	Mar	CMFD
>A>	AB		400MG	A075211	001	Sep 28, 1998	Mar	CMFD
>D>		@	800MG	A075211	002	Sep 28, 1998	Mar	CMFD
>A>	AB		800MG	A075211	002	Sep 28, 1998	Mar	CMFD

ADAPALENE

LOTION; TOPICAL
DIFFERIN

>A>		+ GALDERMA R AND D	0.1%	N022502	001	Mar 17, 2010	Mar	NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

>A>	AN	APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010	Mar	NEWA
>A>	AN		EQ 0.042% BASE	A078623	002	Apr 05, 2010	Mar	NEWA
>A>	AN	NEPHRON	EQ 0.021% BASE	A076355	002	Mar 31, 2010	Mar	NEWA

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

	AB	CADISTA PHARMS	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jan	NEWA
	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jan	NEWA
	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jan	NEWA
	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jan	NEWA

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL
ALPRAZOLAM

	AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Feb	NEWA
	AB		0.5MG	A078561	002	Mar 16, 2010	Feb	NEWA
	AB		1MG	A078561	003	Mar 16, 2010	Feb	NEWA
	AB		2MG	A078561	004	Mar 16, 2010	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>D>	AB	KALI LABS INC	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Mar	CAHN
>D>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Mar	CAHN
>D>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Mar	CAHN
>A>	AB	VINTAGE	EQ 2.5MG BASE	A078414	001	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 5MG BASE	A078414	002	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 10MG BASE	A078414	003	Apr 07, 2010	Mar	NEWA
>A>	AB	WORLD GEN	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Mar	CAHN
>A>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Mar	CAHN
>A>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Mar	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183	001	Apr 15, 2010	Mar	NEWA
>A>	AB		EQ 5MG BASE;10MG	A077183	002	Apr 15, 2010	Mar	NEWA
>A>	AB		EQ 5MG BASE;20MG	A077183	003	Apr 15, 2010	Mar	NEWA
>A>	AB		EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010	Mar	NEWA
	AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010	Jan	NEWA

CAPSULE; ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	LUPIN PHARMS	EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010	Jan	NEWA
AB		EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010	Jan	NEWA
AB		EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010	Jan	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL
TRIMOX

@ APOTHECON	50MG/ML	A061886	001		Feb	DISC
@	125MG/5ML	A061886	002		Feb	DISC
@	125MG/5ML	A062885	001	Mar 08, 1988	Feb	DISC
@	250MG/5ML	A061886	003		Feb	DISC
@	250MG/5ML	A062885	002	Mar 08, 1988	Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AUGMENTIN '125'

AB	GLAXOSMITHKLINE	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Feb	CMFD

AUGMENTIN '250'

AB	GLAXOSMITHKLINE	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	Feb	CMFD

TABLET; ORAL
AUGMENTIN '250'

AB	GLAXOSMITHKLINE	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb	CMFD

AUGMENTIN '500'

AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb	CMFD

AUGMENTIN '875'

AB	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CMFD

TABLET, EXTENDED RELEASE; ORAL
AUGMENTIN XR

AB	GLAXOSMITHKLINE	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Feb	CMFD

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
ABELCET

+	SIGMA TAU	5MG/ML	N050724	001	Nov 20, 1995	Feb	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

>A>	AP	BIONICHE PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Mar	CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Mar	CAHN
>D>	AP	GENERAMEDIX	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Mar	CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Mar	CAHN

ARMODAFINIL

TABLET; ORAL
NUVIGIL

@ CEPHALON	100MG	N021875	002	Mar 26, 2009	Feb	DISC
@	200MG	N021875	005	Mar 26, 2009	Feb	DISC

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

>D>		NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009	Mar	CRLD
>A>	+		20MG;120MG	N022268	001	Apr 07, 2009	Mar	CRLD

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

		PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010	Feb	NEWA
	+		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010	Feb	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	WATSON PHARMS	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Feb	CTEC

LANORINAL

AA		LANNETT	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Feb	CTEC

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983	Feb	CTEC
AA	+	WEST WARD	325MG;50MG;40MG	A086162	002	Feb 16, 1984	Feb	CTEC

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTELIN

AB	+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Jan	CTEC

AZELASTINE HYDROCHLORIDE

AB		APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954	001	Apr 30, 2009	Jan	CMFD

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>A>	AP	GENERAMEDIX	EQ 500MG BASE/VIAL	A065501	001	Nov 09, 2009	Mar	CAHN
>D>	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A065501	001	Nov 09, 2009	Mar	CAHN
	AP		EQ 500MG BASE/VIAL	A065501	001	Nov 09, 2009	Feb	CAHN

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

	+	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010	Feb	NEWA

BACLOFEN

TABLET; ORAL

BACLOFEN

AB		MATRIX LABS LTD	10MG	A090334	001	Feb 18, 2010	Jan	NEWA
AB			20MG	A090334	002	Feb 18, 2010	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

		@ SCHWARZ PHARMA	10MG	N021589	001	Oct 30, 2003	Jan	DISC
		@	20MG	N021589	002	Oct 30, 2003	Jan	DISC

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+		TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Feb	CAHN

QVAR 80

+		TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

>A>	AB		HUAHAI US INC	5MG	A076118	001	Feb 11, 2004	Mar	CAHN
>A>	AB			10MG	A076118	002	Feb 11, 2004	Mar	CAHN
>A>	AB			20MG	A076118	003	Feb 11, 2004	Mar	CAHN
>A>	AB			40MG	A076118	004	Feb 11, 2004	Mar	CAHN
>D>	AB		KV PHARM	5MG	A076118	001	Feb 11, 2004	Mar	CAHN
>D>	AB			10MG	A076118	002	Feb 11, 2004	Mar	CAHN
>D>	AB			20MG	A076118	003	Feb 11, 2004	Mar	CAHN
>D>	AB			40MG	A076118	004	Feb 11, 2004	Mar	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

>A>	AP		PHARMAFORCE	1MG/ML	A091152	001	Mar 29, 2010	Mar	NEWA

TABLET; ORAL

BENZTROPINE MESYLATE

>A>	AA		INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	NEWA
>A>	AA			1MG	A090294	002	Mar 29, 2010	Mar	NEWA
>A>	AA			2MG	A090294	003	Mar 29, 2010	Mar	NEWA
	AA	+	LANNETT	0.5MG	A088877	001	Apr 11, 1985	Feb	CAHN
	AA	+		1MG	A088894	001	Apr 11, 1985	Feb	CAHN
	AA	+		2MG	A088895	001	Apr 11, 1985	Feb	CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

>A>	AB		LUITPOLD	3MG/ML;EQ 3MG BASE/ML	A090747	001	Jul 31, 2009	Mar	CAHN
>D>	AB		PHARMAFORCE	3MG/ML;EQ 3MG BASE/ML	A090747	001	Jul 31, 2009	Mar	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

	AT		AKORN	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jan	CTNA
	AT		NOVEX	EQ 0.5% BASE	A075446	001	Sep 28, 2000	Jan	CTNA
	AT		WOCKHARDT	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Jan	CAIN

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

	AB		MIKAH PHARMA	10MG	A075541	001	Oct 22, 1999	Feb	CAHN
	AB	+		20MG	A075541	002	Oct 22, 1999	Feb	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

>D>		+	HOSPIRA	0.5%;0.005MG/ML	A071168	001	Jun 16, 1988	Mar	CTEC
>A>	AP	+		0.5%;0.005MG/ML	A071168	001	Jun 16, 1988	Mar	CTEC
>D>		@		0.5%;0.005MG/ML	A071170	001	Jun 16, 1988	Mar	CMFD

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

>A>	AP		HOSPIRA	0.5%;0.005MG/ML	A071170	001	Jun 16, 1988	Mar	CMFD

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

>A>	AB1		MYLAN	100MG	A090325	001	Apr 08, 2010	Mar	NEWA
>A>	AB1			150MG	A090325	002	Apr 08, 2010	Mar	NEWA
>A>	AB1			200MG	A090325	003	Apr 08, 2010	Mar	NEWA
>A>	AB1		SUN PHARMA GLOBAL	100MG	A078866	001	Apr 06, 2010	Mar	NEWA
>A>	AB1			150MG	A078866	002	Apr 06, 2010	Mar	NEWA
>A>	AB1			200MG	A078866	003	Apr 06, 2010	Mar	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR

>D>	AB		BRISTOL MYERS SQUIBB	10MG	N018731	002	Sep 29, 1986	Mar	DISC
>A>			@	10MG	N018731	002	Sep 29, 1986	Mar	DISC
			@	15MG	N018731	003	Apr 22, 1996	Feb	DISC

BUSPIRONE HYDROCHLORIDE

>D>	AB		IVAX SUB TEVA PHARMS	15MG	A075385	003	Mar 01, 2002	Mar	CRLD
>A>	AB	+		15MG	A075385	003	Mar 01, 2002	Mar	CRLD
>D>	AB	+	TEVA	30MG	A075022	004	Mar 25, 2004	Mar	CRLD
>A>	AB			30MG	A075022	004	Mar 25, 2004	Mar	CRLD
	AB	+		30MG	A075022	004	Mar 25, 2004	Feb	CRLD

CABERGOLINE

TABLET; ORAL
CABERGOLINE

>A>	AB		IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar	CAHN
>D>	AB		WATSON LABS	0.5MG	A077843	001	Jul 03, 2007	Mar	CAHN

CALCIPOTRIENE

>A> OINTMENT; TOPICAL
>A> CALCIPOTRIENE

>A>		+	GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010	Mar	NEWA

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION
BALANCED SALT

	AT		B BRAUN	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A091387	001	Feb 03, 2010	Jan	NEWA

CARBINOXAMINE MALEATE

TABLET; ORAL
CARBINOXAMINE MALEATE

>A>	AA		INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>A>	AP		BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	CAHN
>A>	AP			150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	CAHN
>A>	AP			450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>D>	AP		GENERAMEDIX	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	CAHN
>D>	AP			150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	CAHN
>D>	AP			450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	CAHN

>A> CARGLUMIC ACID

>A> TABLET; ORAL
>A> CARBAGLU

>A>		+	ORPHAN EUROPE	200MG	N022562	001	Mar 18, 2010	Mar	NEWA

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
COREG CR

		+	SB PHARMCO	40MG	N022012	003	Oct 20, 2006	Feb	CRLD
				80MG	N022012	004	Oct 20, 2006	Feb	CRLD

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL
CEFACLOR

>D>	AB	+	PAR PHARM	EQ 500MG BASE	A065057	001	Jan 05, 2001	Mar	CAHN
>A>	AB	+	WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001	Mar	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

>D>	AB		TEVA PHARMS	EQ 500MG BASE	A065282	001	Jan 20, 2006	Mar	CRLD
>A>	AB	+		EQ 500MG BASE	A065282	001	Jan 20, 2006	Mar	CRLD

FOR SUSPENSION; ORAL
CEFADROXIL

	AB	+	LUPIN	EQ 500MG BASE/5ML	A065396	002	Feb 21, 2008	Jan	CRLD
			DURICEF						
			@ WARNER CHILCOTT	EQ 250MG BASE/5ML	N050527	003		Jan	DISC
			@	EQ 500MG BASE/5ML	N050527	001		Jan	DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

	AP		CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010	Jan	NEWA

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

	AP		HIKMA FARMACEUTICA	EQ 1GM BASE/VIAL	A065238	001	Mar 12, 2010	Feb	NEWA
	AP			EQ 2GM BASE/VIAL	A065238	002	Mar 12, 2010	Feb	NEWA
	AP			EQ 10GM BASE/VIAL	A065239	001	Mar 02, 2010	Feb	NEWA

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

	AB	+	LUPIN	250MG/5ML	A065261	002	Dec 19, 2005	Feb	CTEC

TABLET; ORAL
CEFPROZIL

	AB	+	LUPIN	500MG	A065276	002	Dec 08, 2005	Feb	CRLD

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

AA		ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Jan	NEWA

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX

AT		PERRIGO	1%	A078594	001	Feb 16, 2010	Jan	NEWA

SOLUTION; TOPICAL
CICLOPIROX

AT		VERSAPHARM	8%	A078975	001	Feb 17, 2010	Jan	NEWA

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO

AB	+	BAYER HLTHCARE	EQ 500MG BASE	N019537	003	Oct 22, 1987	Feb	CRLD
AB			EQ 750MG BASE	N019537	004	Oct 22, 1987	Feb	CRLD

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL
CLINDAMYCIN PHOSPHATE

>A>								
>A>	AT	COBREK PHARMS	1%	A090785	001	Mar 31, 2010	Mar	NEWA

EVOCLIN

>D>	+	STIEFEL LABS INC	1%	N050801	001	Oct 22, 2004	Mar	CFTG
>A>	AT +		1%	N050801	001	Oct 22, 2004	Mar	CFTG

CREAM; VAGINAL
CLINDAMYCIN PHOSPHATE

>D>	AB	ALTANA PHARMA	EQ 2% BASE	A065139	001	Dec 27, 2004	Mar	CAHN
>A>	AB	NYCOMED US	EQ 2% BASE	A065139	001	Dec 27, 2004	Mar	CAHN

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB	FOUGERA	0.05%	A074407	001	Feb 23, 1996	Mar	CAHN
>A>	AB	NYCOMED US	0.05%	A074407	001	Feb 23, 1996	Mar	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

>A>	AP	BIONICHE PHARMA USA	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Mar	CAHN
>A>	AP +		5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Mar	CAHN
>D>	AP	XANODYNE PHARM	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Mar	CAHN
>D>	AP +		5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Mar	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>A>	AA	SUN PHARM INDS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Mar	NEWA

COSYNTROPIN

INJECTABLE; INJECTION
COSYNTROPIN

>A>	AP	BIONICHE PHARMA	0.25MG/VIAL	A090574	001	Dec 17, 2009	Mar	CAHN
>D>	AP	GENERAMEDIX	0.25MG/VIAL	A090574	001	Dec 17, 2009	Mar	CAHN

CYANOCOBALAMIN

SPRAY, METERED; NASAL

			CALOMIST						
		@	FLEMING	25MCG/SPRAY	N022102	001	Jul 27, 2007	Jan	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

			CYTOXAN						
AP	+		BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb	CMFD
AP	+			1GM/VIAL	N012142	004	Aug 30, 1982	Feb	CMFD
AP	+			2GM/VIAL	N012142	005	Aug 30, 1982	Feb	CMFD
			LYOPHILIZED CYTOXAN						
		@	BAXTER HLTHCARE	100MG/VIAL	N012142	006	Dec 05, 1985	Feb	DISC
		@		200MG/VIAL	N012142	007	Dec 10, 1985	Feb	DISC
		@		500MG/VIAL	N012142	008	Jan 04, 1984	Feb	DISC
		@		1GM/VIAL	N012142	010	Sep 24, 1985	Feb	DISC
		@		2GM/VIAL	N012142	009	Dec 10, 1984	Feb	DISC

CYTARABINE

INJECTABLE; INJECTION

			CYTARABINE						
>D>			HOSPIRA	20MG/ML	A072168	001	Aug 31, 1990	Mar	CRLD
>A>	AP	+		20MG/ML	A072168	001	Aug 31, 1990	Mar	CRLD

DACTINOMYCIN

INJECTABLE; INJECTION

			COSMEGEN						
>D>		+	LUNDBECK INC	0.5MG/VIAL	N050682	001		Mar	CFTG
>A>	AP	+		0.5MG/VIAL	N050682	001		Mar	CFTG
>A>			DACTINOMYCIN						
>A>	AP		BEDFORD	0.5MG/VIAL	A090304	001	Mar 16, 2010	Mar	NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

			AMPYRA						
		+	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	NEWA

DESLORATADINE

TABLET; ORAL

			CLARINEX						
AB	+		SCHERING PLOUGH	5MG	N021165	001	Dec 21, 2001	Jan	CFTG
			DESLORATADINE						
AB			ORCHID HLTHCARE	5MG	A078357	001	Feb 19, 2010	Jan	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

			STIMATE (NEEDS NO REFRIGERATION)						
		@	CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007	Jan	DISC

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

>A>			DEXILANT						
>A>			TAKEDA PHARMS	30MG	N022287	001	Jan 30, 2009	Mar	CTNA
>A>		+		60MG	N022287	002	Jan 30, 2009	Mar	CTNA

		CAPSULE, DELAYED RELEASE; ORAL							
>D>		KAPIDEX							
>D>		TAKEDA PHARMS	30MG	N022287	001	Jan 30, 2009	Mar	CTNA	
>D>	+		60MG	N022287	002	Jan 30, 2009	Mar	CTNA	
		DEXMEDETOMIDINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		PRECEDEX							
	+	HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038	001	Dec 17, 1999	Jan	CAIN	
		DIAZOXIDE							
		CAPSULE; ORAL							
		PROGLYCEM							
	@	TEVA BRANDED PHARM	50MG	N017425	001		Feb	CAHN	
	@		100MG	N017425	002		Feb	CAHN	
		DICLOFENAC POTASSIUM							
		FOR SOLUTION; ORAL							
		CAMBIA							
>D>	+	KOWA PHARMS	50MG	N022165	001	Jun 17, 2009	Mar	CAHN	
>A>	+	NAUTILUS NEUROSCIENC	50MG	N022165	001	Jun 17, 2009	Mar	CAHN	
		TABLET; ORAL							
		DICLOFENAC POTASSIUM							
	@	SANDOZ	50MG	A075582	001	Feb 23, 2001	Jan	DISC	
		DIDANOSINE							
		CAPSULE, DELAYED REL PELLETS; ORAL							
		DIDANOSINE							
>A>	AB	MATRIX LABS LTD	125MG	A090788	001	Apr 08, 2010	Mar	NEWA	
>A>	AB		200MG	A090788	002	Apr 08, 2010	Mar	NEWA	
>A>	AB		250MG	A090788	003	Apr 08, 2010	Mar	NEWA	
>A>	AB		400MG	A090788	004	Apr 08, 2010	Mar	NEWA	
		DIFLORASONE DIACETATE							
		CREAM; TOPICAL							
		DIFLORASONE DIACETATE							
>D>	AB1	ALTANA	0.05%	A075187	001	Mar 30, 1998	Mar	CRLD	
>A>	AB1 +		0.05%	A075187	001	Mar 30, 1998	Mar	CRLD	
		PSORCON							
	@	SANOFI AVENTIS US	0.05%	N020205	001	Nov 20, 1992	Feb	DISC	
		DILTIAZEM HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE; ORAL							
		CARDIZEM LA							
	AB	BIOVAIL LABS INTL	120MG	N021392	001	Feb 06, 2003	Feb	CFTG	
	AB		180MG	N021392	002	Feb 06, 2003	Feb	CFTG	
	AB		240MG	N021392	003	Feb 06, 2003	Feb	CFTG	
	AB		300MG	N021392	004	Feb 06, 2003	Feb	CFTG	
	AB		360MG	N021392	005	Feb 06, 2003	Feb	CFTG	
	AB +		420MG	N021392	006	Feb 06, 2003	Feb	CFTG	
		DILTIAZEM HYDROCHLORIDE							
	AB	WATSON LABS FLORIDA	120MG	A077686	006	Mar 15, 2010	Feb	NEWA	
	AB		180MG	A077686	005	Mar 15, 2010	Feb	NEWA	
	AB		240MG	A077686	004	Mar 15, 2010	Feb	NEWA	
	AB		300MG	A077686	003	Mar 15, 2010	Feb	NEWA	

TABLET, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB	WATSON LABS FLORIDA	360MG	A077686	002	Mar 15, 2010	Feb	NEWA
AB		420MG	A077686	001	Mar 15, 2010	Feb	NEWA

DOXEPIN HYDROCHLORIDE

TABLET; ORAL
SILENOR

>A>	SOMAXON	EQ 3MG BASE	N022036	001	Mar 17, 2010	Mar	NEWA
>A> +		EQ 6MG BASE	N022036	002	Mar 17, 2010	Mar	NEWA

ELTROMBOPAG OLAMINE

TABLET; ORAL
PROMACTA

>A>	GLAXOSMITHKLINE	EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	NEWA

>D> ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL

>D> +	ASTRAZENECA	5MG;5MG	N020668	001	Dec 27, 1996	Mar	DISC
>A>	@	5MG;5MG	N020668	001	Dec 27, 1996	Mar	DISC

EPINEPHRINE

INJECTABLE; IM-SC
ADRENACLICK

>A> +	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	NEWA
>A> +		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	NEWA

TWINJECT 0.15

+	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Jan	CAHN

TWINJECT 0.3

+	SHIONOGI PHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Jan	CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

>A> AP	BIONICHE PHARMA USA	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Mar	CAHN
>A> AP		200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Mar	CAHN
>D> AP	GENERAMEDIX	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Mar	CAHN
>D> AP		200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Mar	CAHN
>A> AP	X GEN PHARMS	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	NEWA
>A> AP		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

AO	PHARMAFORCE	20MG/ML	A090920	001	Jan 19, 2010	Jan	NEWA
AO		40MG/ML	A090920	002	Jan 19, 2010	Jan	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL

	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010	Feb	NEWA

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010	Jan	NEWA

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL
AB WATSON LABS 0.035MG;0.4MG A078323 001 Feb 04, 2010 Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
AB WATSON LABS 0.02MG;1MG A078267 001 Sep 01, 2009 Jan CDFR

TABLET; ORAL-28
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
>A> AB WATSON LABS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A076629 001 Mar 18, 2010 Mar NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
AB VINTAGE 0.02MG;1MG A077077 001 May 20, 2005 Feb CAHN
AB 0.03MG;1.5MG A077075 001 Apr 28, 2005 Feb CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
PREVIFEM
AB VINTAGE 0.035MG;0.25MG A076334 001 Jan 09, 2004 Feb CAHN
TRI-PREVIFEM
AB VINTAGE 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG A076335 001 Mar 26, 2004 Feb CAHN

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE
AP + BAXTER HLTHCARE 10MG/ML A075488 001 Apr 16, 2001 Feb CRLD
AP + 10MG/ML A075799 001 Apr 30, 2002 Feb CRLD
FAMOTIDINE PRESERVATIVE FREE
AP + BAXTER HLTHCARE 10MG/ML A075486 001 Apr 16, 2001 Feb CRLD
AP + 10MG/ML A075789 001 Apr 30, 2002 Feb CRLD
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER
AP + BAXTER HLTHCARE 0.4MG/ML A075591 001 May 10, 2001 Feb CRLD

TABLET, ORALLY DISINTEGRATING; ORAL
FLUXID
@ SCHWARZ PHARMA 20MG N021712 001 Sep 24, 2004 Jan DISC
@ 40MG N021712 002 Sep 24, 2004 Jan DISC

FENOFIBRATE

CAPSULE; ORAL
ANTARA (MICRONIZED)
LUPIN ATLANTIS 43MG N021695 001 Nov 30, 2004 Jan CAHN
@ 87MG N021695 002 Nov 30, 2004 Jan CAHN
+ 130MG N021695 003 Nov 30, 2004 Jan CAHN

TABLET; ORAL
FENOGLIDE
SHIONOGI PHARMA 40MG N022118 001 Aug 10, 2007 Jan CAHN
+ 120MG N022118 002 Aug 10, 2007 Jan CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA D 24 HOUR
>D> + SANOFI AVENTIS US 180MG;240MG N021704 001 Oct 19, 2004 Mar CFTG
>A> AB + 180MG;240MG N021704 001 Oct 19, 2004 Mar CFTG
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
>A> AB DR REDDYS LABS LTD 180MG;240MG A079043 001 Mar 17, 2010 Mar NEWA

FINASTERIDE

TABLET; ORAL
FINASTERIDE

AB		ACCORD HLTHCARE INC	5MG	A090121	001	Feb 23, 2010	Feb	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan	CTNA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004	Feb	DISC
	@		400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004	Feb	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROSPAN HFA

	+	ACTON PHARMS	EQ 78MCG BASE/INH	N021247	001	Jan 27, 2006	Feb	CAHN

SPRAY, METERED; NASAL
NASAREL

AB	+	TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995	Feb	CAHN

FLUOROURACIL

CREAM; TOPICAL
FLUOROURACIL

AB		TARO	5%	A090368	001	Mar 05, 2010	Feb	NEWA

INJECTABLE; INJECTION
FLUOROURACIL

>A>	AP	+	BIONICHE PHARMA	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Mar	CAHN
>A>	AP	+		1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Mar	CAHN
>A>	AP	+		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007	Mar	CAHN
>A>	AP	+		5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Mar	CAHN
>D>	AP	+	GENERAMEDIX	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Mar	CAHN
>D>	AP	+		1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Mar	CAHN
>D>	AP	+		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007	Mar	CAHN
>D>	AP	+		5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
>A> FLUOXETINE HYDROCHLORIDE

>A>	AB		BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Mar	NEWA
>A>	AB		DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Mar	NEWA

PROZAC WEEKLY

>D>		+	LILLY	EQ 90MG BASE	N021235	001	Feb 26, 2001	Mar	CFTG
>A>	AB	+		EQ 90MG BASE	N021235	001	Feb 26, 2001	Mar	CFTG

SOLUTION; ORAL
FLUOXETINE HYDROCHLORIDE

AA			LANNETT	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Feb	CAHN

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	+	PHARMAX	1MG	A040625	001	Jul 21, 2005	Jan	CRLD
AA	+	WATSON LABS	1MG	A080680	001		Jan	CMFD

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

>A>	AP	BIONICHE PHARMA USA	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Mar	CAHN
>D>	AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Mar	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

	AP	PHARMAFORCE	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007	Feb	CAHN

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK IN PLASTIC CONTAINER

>D>	+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Mar	CPOT
>A>	+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Mar	CPOT

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

>D>		@ ROCHE PALO	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Mar	CMFD
>A>	+		EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Mar	CMFD

GANCICLOVIR SODIUM

>D>		BEDFORD	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Mar	DISC
>A>		@	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Mar	DISC

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

>D>		@ DAVA PHARMS INC	600MG	A074270	001	Sep 27, 1993	Mar	CMFD
>A>	AB		600MG	A074270	001	Sep 27, 1993	Mar	CMFD

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

		@ TEVA	1.25MG;250MG	A076821	001	Jan 27, 2005	Jan	DISC
		@	2.5MG;500MG	A076821	002	Jan 27, 2005	Jan	DISC
		@	5MG;500MG	A076821	003	Jan 27, 2005	Jan	DISC

GLYCOPYRROLATE

TABLET; ORAL

ROBINUL

	AA	+ SHIONOGI PHARMA	1MG	N012827	001		Jan	CAHN

ROBINUL FORTE

	AA	+ SHIONOGI PHARMA	2MG	N012827	002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	SAGENT STRIDES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A091136	001	Apr 09, 2010	Mar	NEWA
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091136	002	Apr 09, 2010	Mar	NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137	002	Apr 09, 2010	Mar	NEWA

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

		FULVICIN-U/F						
	@	ELORAC	250MG	A060569	002		Feb	CAHN
	@		500MG	A060569	001		Feb	CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

		GUANFACINE HYDROCHLORIDE						
AB		MIKAH PHARMA	EQ 1MG BASE	A074673	001	Feb 28, 1997	Feb	CAHN
AB			EQ 2MG BASE	A074673	002	Feb 28, 1997	Feb	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

		HALDOL						
	@	ORTHO MCNEIL JANSSEN	EQ 5MG BASE/ML	N015923	001		Feb	DISC
		HALOPERIDOL						
AP	+	TEVA PARENTERAL	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Feb	CRLD

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HYDROCHLORIDE						
AA		HERITAGE PHARMS INC	10MG	A086242	001	Feb 04, 2010	Jan	NEWA
AA			100MG	A086242	004	Feb 04, 2010	Jan	NEWA
AA		ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Feb	NEWA
AA			25MG	A040858	002	Feb 26, 2010	Feb	NEWA
AA			50MG	A040858	003	Feb 26, 2010	Feb	NEWA
AA			100MG	A040858	004	Feb 26, 2010	Feb	NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

		HYDROCHLOROTHIAZIDE						
AB		UNICHEM	12.5MG	A090510	001	Jan 19, 2010	Jan	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

		LISINOPRIL AND HYDROCHLOROTHIAZIDE						
	@	TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002	Jan	DISC
	@		12.5MG;20MG	A075869	002	Jul 01, 2002	Jan	DISC
	@		25MG;20MG	A075869	003	Jul 01, 2002	Jan	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

		HYZAAR						
>D>		MERCK	12.5MG;50MG	N020387	001	Apr 28, 1995	Mar	CFTG
>A>	AB		12.5MG;50MG	N020387	001	Apr 28, 1995	Mar	CFTG
>D>			12.5MG;100MG	N020387	003	Oct 20, 2005	Mar	CFTG
>A>	AB		12.5MG;100MG	N020387	003	Oct 20, 2005	Mar	CFTG
>D>	+		25MG;100MG	N020387	002	Nov 10, 1998	Mar	CFTG
>A>	AB +		25MG;100MG	N020387	002	Nov 10, 1998	Mar	CFTG
>A>		LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE						
>A>	AB	MYLAN	12.5MG;100MG	A091652	002	Apr 06, 2010	Mar	NEWA
>A>	AB	ROXANE	12.5MG;100MG	A077732	001	Apr 06, 2010	Mar	NEWA
>A>	AB	TEVA PHARMS	12.5MG;50MG	A077157	001	Apr 06, 2010	Mar	NEWA
>A>	AB		12.5MG;100MG	A077157	002	Apr 06, 2010	Mar	NEWA

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>A>	AB		TEVA PHARMS	25MG;100MG	A077157	003	Apr 06, 2010	Mar	NEWA
>A>	AB		TORRENT PHARMS	12.5MG;100MG	A090528	003	Apr 06, 2010	Mar	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	AB	+	MYLAN	25MG;100MG	A076792	002	Aug 20, 2004	Jan	CRLD
				50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB		GLENMARK PHARMS	12.5MG;7.5MG	A090718	001	Mar 17, 2010	Mar	NEWA
>A>	AB			12.5MG;15MG	A090718	002	Mar 17, 2010	Mar	NEWA
>A>	AB			25MG;15MG	A090718	003	Mar 17, 2010	Mar	NEWA

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

	AT	+	FOUGERA	1%	A080693	003		Feb	CRLD
	AT	+		2.5%	A089414	001	Dec 16, 1986	Feb	CRLD

HYTONE

		@	SANOFI AVENTIS US	1%	A080472	003		Feb	DISC
		@		2.5%	A080472	004		Feb	DISC

LOTION; TOPICAL
HYTONE

		@	SANOFI AVENTIS US	1%	A080473	003		Feb	DISC
		@		2.5%	A080473	004	Nov 30, 1982	Feb	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HYDROCHLORIDE

>A>	AP		AKORN	10MG/ML	A078228	001	Apr 14, 2010	Mar	NEWA
>A>	AP			10MG/ML	A078261	001	Apr 14, 2010	Mar	NEWA

>A> TABLET, EXTENDED RELEASE; ORAL
>A> EXALGO

>A>			MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Mar	NEWA
>A>				12MG	N021217	002	Mar 01, 2010	Mar	NEWA
>A>		+		16MG	N021217	003	Mar 01, 2010	Mar	NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN

	AB		CONTRACT PHARMACAL	400MG	A071267	001	Oct 15, 1986	Jan	CAHN
	AB			600MG	A071268	001	Oct 15, 1986	Jan	CAHN
	AB			800MG	A072300	001	Jul 01, 1988	Jan	CAHN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION
IBUTILIDE FUMARATE

>A>	AP		BIONICHE PHARMA USA	0.1MG/ML	A090924	001	Jan 11, 2010	Mar	CAHN
>D>	AP		GENERAMEDIX	0.1MG/ML	A090924	001	Jan 11, 2010	Mar	CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

AP		BAXTER HLTHCARE	1GM/VIAL	N019763	001	Dec 30, 1988	Feb	CMFD
AP			3GM/VIAL	N019763	002	Dec 30, 1988	Feb	CMFD

IFOSFAMIDE

AP	+	APP PHARMS	1GM/VIAL	A076078	001	May 28, 2002	Feb	CTEC
	+		1GM/VIAL	A076078	001	May 28, 2002	Jan	CTEC
AP			1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009	Jan	CPOT
AP	+		3GM/VIAL	A076078	002	May 28, 2002	Feb	CTEC
	+		3GM/VIAL	A076078	002	May 28, 2002	Jan	CTEC
AP			3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009	Jan	CPOT
AP	+	TEVA PARENTERAL	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Jan	CTEC
AP	+		3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Jan	CTEC

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

	@	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992	Feb	DISC
	@		3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992	Feb	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB		LUPIN LTD	10MG	A090443	001	Mar 11, 2010	Feb	NEWA
AB			25MG	A090442	001	Mar 11, 2010	Feb	NEWA
AB			50MG	A090441	001	Mar 11, 2010	Feb	NEWA

IMIQUIMOD

CREAM; TOPICAL

ALDARA

AB	+	GRACEWAY	5%	N020723	001	Feb 27, 1997	Feb	CFTG

IMIQUIMOD

AB		NYCOMED US	5%	A078548	001	Feb 25, 2010	Feb	NEWA

ZYCLARA

>A>	+	GRACEWAY	3.75%	N022483	001	Mar 25, 2010	Mar	NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

	@	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000	Feb	DISC
	+	BEDFORD	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Feb	CTEC

INDOMETHACIN

INJECTABLE; INJECTION

INDOMETHACIN

>A>	+	APP PHARMS	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>D>	AP	SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008	Mar	DISC
>A>	@		40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008	Mar	DISC
>D>	AP		100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008	Mar	DISC
>A>	@		100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008	Mar	DISC

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE

>A>	AB	+	CARACO	40MG	A040009	001	Dec 30, 1998	Mar	CAHN
>D>	AB	+	INWOOD LABS	40MG	A040009	001	Dec 30, 1998	Mar	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCLORIDE

	AP		SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	NEWA

TABLET; ORAL
TRANDATE

	AB	+	PROMETHEUS LABS	200MG	N018716	002	Aug 01, 1984	Feb	CRLD
	AB			300MG	N018716	003	Aug 01, 1984	Feb	CRLD

LENALIDOMIDE

CAPSULE; ORAL
REVLIMID

		+	CELGENE	5MG	N021880	001	Dec 27, 2005	Jan	CRLD

LEVETIRACETAM

SOLUTION; ORAL
LEVETIRACETAM

	AA		WOCKHARDT	100MG/ML	A090028	001	Mar 03, 2010	Feb	NEWA

TABLET; ORAL
LEVETIRACETAM

	AB		TARO	250MG	A078960	004	Feb 01, 2010	Jan	NEWA
	AB			500MG	A078960	003	Feb 01, 2010	Jan	NEWA
	AB			750MG	A078960	002	Feb 01, 2010	Jan	NEWA
	AB			1GM	A078960	001	Feb 01, 2010	Jan	NEWA

LEVOTHYROXINE SODIUM

CAPSULE; ORAL
TIROSINT

			INST BIOCHIMIQUE	0.013MG	N022121	001	Aug 01, 2007	Feb	CMFD
				0.025MG	N021924	002	Oct 13, 2006	Feb	CMFD
				0.05MG	N021924	003	Oct 13, 2006	Feb	CMFD
				0.075MG	N021924	004	Oct 13, 2006	Feb	CMFD
				0.088MG	N021924	010	Oct 02, 2009	Feb	NEWA
				0.1MG	N021924	005	Oct 13, 2006	Feb	CMFD
				0.112MG	N021924	008	Oct 02, 2009	Feb	NEWA
				0.125MG	N021924	006	Oct 13, 2006	Feb	CMFD
				0.137MG	N021924	009	Oct 02, 2009	Feb	NEWA
				0.15MG	N021924	007	Oct 13, 2006	Feb	CMFD

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
LIDOCAINE AND PRILOCAINE

>D>	AB		ALTANA	2.5%;2.5%	A076453	001	Aug 18, 2003	Mar	CAHN
>A>	AB		NYCOMED US	2.5%;2.5%	A076453	001	Aug 18, 2003	Mar	CAHN

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS
VICTOZA

		+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Jan	NEWA

LISINOPRIL

TABLET; ORAL

LISINOPRIL

		@	TEVA	2.5MG	A075783	001	Jul 01, 2002	Jan	DISC
		@		5MG	A075783	002	Jul 01, 2002	Jan	DISC
		@		10MG	A075783	003	Jul 01, 2002	Jan	DISC
		@		20MG	A075783	004	Jul 01, 2002	Jan	DISC
		@		30MG	A075783	005	Jul 01, 2002	Jan	DISC
		@		40MG	A075783	006	Jul 01, 2002	Jan	DISC

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

		@	NOVEN THERAP	300MG	N016860	001		Jan	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

>D>			MERCK	25MG	N020386	001	Apr 14, 1995	Mar	CFTG
>A>	AB			25MG	N020386	001	Apr 14, 1995	Mar	CFTG
>D>				50MG	N020386	002	Apr 14, 1995	Mar	CFTG
>A>	AB			50MG	N020386	002	Apr 14, 1995	Mar	CFTG
>D>		+		100MG	N020386	003	Oct 13, 1998	Mar	CFTG
>A>	AB	+		100MG	N020386	003	Oct 13, 1998	Mar	CFTG
>A>			LOSARTAN POTASSIUM						
>A>	AB		TEVA	25MG	A076958	001	Apr 06, 2010	Mar	NEWA
>A>	AB			50MG	A076958	002	Apr 06, 2010	Mar	NEWA
>A>	AB			100MG	A076958	003	Apr 06, 2010	Mar	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

	AA	+	PFIZER	50MG	N010721	001	Jan 20, 1982	Jan	CMFD

TABLET, CHEWABLE; ORAL

ANTIVERT

		@	PFIZER	25MG	N010721	005		Jan	DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP		BIONICHE PHARMA USA	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009	Mar	CAHN
>D>	AP		GENERAMEDIX	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009	Mar	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

>A>			MEMANTINE HYDROCHLORIDE						
>A>	AB		DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Mar	NEWA
>A>	AB			10MG	A090048	002	Apr 14, 2010	Mar	NEWA

NAMENDA

>D>			FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CFTG
>A>	AB			5MG	N021487	001	Oct 16, 2003	Mar	CFTG
>D>		+		10MG	N021487	002	Oct 16, 2003	Mar	CFTG
>A>	AB	+		10MG	N021487	002	Oct 16, 2003	Mar	CFTG

MEPERIDINE HYDROCHLORIDE

SYRUP; ORAL
MEPERIDINE HYDROCHLORIDE

+	ROXANE	50MG/5ML	A088744	001	Jan 30, 1985	Feb		CRLD

TABLET; ORAL
DEMEROL

@	SANOFI AVENTIS US	50MG	N005010	001		Feb		DISC

MEPERIDINE HYDROCHLORIDE

AA	MIKAH PHARMA	50MG	A040331	001	May 28, 1999	Feb		CAHN
AA		100MG	A040331	002	May 28, 1999	Feb		CAHN

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
ASACOL

+	WARNER CHILCOTT INC	400MG	N019651	001	Jan 31, 1992	Feb		CAHN

ASACOL HD

+	WARNER CHILCOTT INC	800MG	N021830	001	May 29, 2008	Feb		CAHN

MESNA

INJECTABLE; INTRAVENOUS
MESNA

>A> AP	SAGENT STRIDES	100MG/ML	A090913	001	Apr 13, 2010	Mar		NEWA

METAXALONE

TABLET; ORAL
>A> METAXALONE

>A> AB	SANDOZ	800MG	A040445	001	Mar 31, 2010	Mar		NEWA

SKELAXIN

>D> +	KING PHARMS	800MG	N013217	003	Aug 30, 2002	Mar		CFTG
>A> AB +		800MG	N013217	003	Aug 30, 2002	Mar		CFTG

METFORMIN HYDROCHLORIDE

TABLET; ORAL
>D> METFORMIN HYDROCHLORIDE

>D> AB	IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007	Mar		DISC
>A>	@	500MG	A078422	001	Aug 06, 2007	Mar		DISC
>D> AB		850MG	A078422	002	Aug 06, 2007	Mar		DISC
>A>	@	850MG	A078422	002	Aug 06, 2007	Mar		DISC
>D> AB		1GM	A078422	003	Aug 06, 2007	Mar		DISC
>A>	@	1GM	A078422	003	Aug 06, 2007	Mar		DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB	TORRENT PHARMS	750MG	A079226	001	Feb 18, 2010	Jan		NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION
DOLOPHINE HYDROCHLORIDE

>A> +	BIONICHE PHARMA	10MG/ML	N021624	001		Mar		CAHN
>D> +	XANODYNE PHARM	10MG/ML	N021624	001		Mar		CAHN

METHENAMINE HIPPURATE

TABLET; ORAL
UREX

AB	CNTY LINE PHARMS	1GM	N016151	001		Feb		CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>A>	AP	+	BIONICHE PHARMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Mar	CAHN
>A>	AP	+	BIONICHE PHARMA USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Mar	CAHN
>A>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Mar	CAHN
>D>	AP	+	GENERAMEDIX	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Mar	CAHN
>D>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Mar	CAHN
>D>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Mar	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

			@ HOSPIRA	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996	Feb	DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

			@ SANDOZ	EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	DISC
			@ WATSON LABS	EQ 10MG BASE	A070511	001	Jan 22, 1986	Jan	DISC

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

>D>			@ PAR PHARM	250MG	A070040	001	Jan 29, 1985	Mar	CAHN
>A>			@ WORLD GEN	250MG	A070040	001	Jan 29, 1985	Mar	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP	+	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834	001	May 28, 2002	Feb	CTEC
	AP	+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834	002	May 28, 2002	Feb	CRLD

MILRINONE LACTATE IN PLASTIC CONTAINER

	AP		HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038	001	Jan 21, 2010	Jan	NEWA
	AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038	002	Jan 21, 2010	Jan	NEWA

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

			@ SANOFI AVENTIS US	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Feb	DISC
			@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Feb	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>A>	AP		BIONICHE PHARMA USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar	CAHN
>A>	AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar	CAHN
>D>	AP		GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar	CAHN
>D>	AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE

>A>	AB	GLENMARK GENERICS	7.5MG	A090416	001	Mar 30, 2010	Mar	NEWA
>A>	AB		15MG	A090416	002	Mar 30, 2010	Mar	NEWA

MORPHINE SULFATE

SOLUTION; ORAL
MORPHINE SULFATE

		ROXANE	20MG/5ML	N022195	002	Mar 17, 2008	Jan	CRLD
	+		100MG/5ML	N022195	003	Jan 25, 2010	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

		@ PURDUE PHARMA LP	15MG	A074862	001	Jul 07, 1998	Feb	CAHN
		@	30MG	A074862	002	Jul 07, 1998	Feb	CAHN
		@	60MG	A074862	003	Jul 07, 1998	Feb	CAHN
		@	100MG	A074769	001	Jul 02, 1998	Feb	CAHN
		@	200MG	A074769	002	Jul 02, 1998	Feb	CAHN

NALIDIXIC ACID

TABLET; ORAL
NEGGRAM

		@ SANOFI AVENTIS US	250MG	N014214	002		Feb	DISC
		@	500MG	N014214	004		Feb	DISC
		@	1GM	N014214	005		Feb	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

	AB	+ WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Feb	CRLD
		TALWIN NX							
		@ SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733	001	Dec 16, 1982	Feb	DISC

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

>A>	AA	OMAN PHARM PRODUCTS	500MG	A065468	001	Mar 29, 2010	Mar	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION
NICARDIPINE HYDROCHLORIDE

>A>	AP	BIONICHE PHARMA USA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Mar	CAHN
>D>	AP	GENERAMEDIX	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Mar	CAHN

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

>A>	AB	INTERGEL PHARM	10MG	A072781	001	Jul 30, 1993	Mar	CAHN
>D>	AB	INVERNESS MEDCL	10MG	A072781	001	Jul 30, 1993	Mar	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR

	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CAHN
		@	10MG	N020356	001	Feb 02, 1995	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
SULAR

	+	SHIONOGI PHARMA	17MG	N020356	007	Jan 02, 2008	Jan	CAHN
	@		20MG	N020356	002	Feb 02, 1995	Jan	CAHN
			25.5MG	N020356	006	Jan 02, 2008	Jan	CAHN
	@		30MG	N020356	003	Feb 02, 1995	Jan	CAHN
	+		34MG	N020356	005	Jan 02, 2008	Jan	CAHN
	@		40MG	N020356	004	Feb 02, 1995	Jan	CAHN

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

	+	SHIONOGI PHARMA	25MG/5ML	N009175	001		Jan	CAHN

NITROGLYCERIN

AEROSOL; SUBLINGUAL
NITROLINGUAL

>A>	@	POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985	Mar	CAHN
>D>	@	SHIONOGI PHARMA	0.4MG/SPRAY	N018705	001	Oct 31, 1985	Mar	CAHN
	@		0.4MG/SPRAY	N018705	001	Oct 31, 1985	Jan	CAHN

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY

>A>	+	POHL BOSKAMP	0.4MG/SPRAY	N018705	002	Jan 10, 1997	Mar	CAHN
>D>	+	SHIONOGI PHARMA	0.4MG/SPRAY	N018705	002	Jan 10, 1997	Mar	CAHN
	+		0.4MG/SPRAY	N018705	002	Jan 10, 1997	Jan	CAHN

OFLOXACIN

TABLET; ORAL
OFLOXACIN

	@	LARKEN LABS	200MG	A076093	001	Sep 02, 2003	Jan	CAHN
	@		300MG	A076093	002	Sep 02, 2003	Jan	CAHN
	@		400MG	A076093	003	Sep 02, 2003	Jan	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

>A>	AB	AUROBINDO PHARMA	4MG	A090469	001	Apr 12, 2010	Mar	NEWA
>A>	AB		8MG	A090469	002	Apr 12, 2010	Mar	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

>A>	AP	LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Mar	NEWA

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE

	AB	GAVIS PHARMS	100MG	A040284	001	Jun 19, 1998	Feb	CAHN

OXALIPLATIN

INJECTABLE; INJECTION
OXALIPLATIN

	AP	+ HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009	Jan	CRLD
	AP	+	100MG/VIAL	A078815	002	Sep 30, 2009	Jan	CRLD

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

	AB	CADISTA PHARMS	150MG	A090239	001	Jan 25, 2010	Jan	NEWA
	AB		300MG	A090239	002	Jan 25, 2010	Jan	NEWA
	AB		600MG	A090239	003	Jan 25, 2010	Jan	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

	+	JOHNSON AND JOHNSON	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jan	CRLD

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

	AP	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Feb	CAHN
	AP		90MG/VIAL	A078300	002	Mar 10, 2009	Feb	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
CREON

>A>		ABBOTT PRODS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Mar	CAHN
>A>			60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Mar	CAHN
>A>	+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Mar	CAHN
>D>		SOLVAY	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Mar	CAHN
>D>			60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Mar	CAHN
>D>	+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Mar	CAHN

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN

	+	SIGMA TAU	250 UNITS/ML	N019818	001	Mar 21, 1990	Feb	CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL
PERINDOPRIL ERBUMINE

	AB	LUPIN LTD	2MG	A078263	001	Jan 27, 2010	Jan	NEWA
	AB		4MG	A078263	002	Jan 27, 2010	Jan	NEWA
	AB		8MG	A078263	003	Jan 27, 2010	Jan	NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

	BC	VALEANT	105MG	A088021	001	Sep 21, 1982	Feb	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

>A>	AA	BARR	15MG	A090591	001	Mar 18, 2010	Mar	NEWA
>A>	AA		30MG	A090591	002	Mar 18, 2010	Mar	NEWA

>A>		POLIDOCANOL							
>A>		SOLUTION; INTRAVENOUS							
>A>		ASCLERA							
>A>		CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010	Mar	NEWA	
>A>	+		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010	Mar	NEWA	
		POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE							
		FOR SOLUTION; ORAL							
		LAX-LYTE WITH FLAVOR PACKS							
	AA	PADDOCK	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	A079232	001	Feb 25, 2010	Feb	NEWA	
>A>		PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE							
>A>	AA	MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	A090409	001	Apr 02, 2010	Mar	NEWA	
		POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS							
		FOR SOLUTION; ORAL							
		PEG 3350 AND ELECTROLYTES							
	AA	MYLAN	236GM;2.97GM;6.74GM;5.86GM;22.74G M	A090928	001	Jan 28, 2010	Jan	NEWA	
		POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES							
	AA	PADDOCK LABS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010	Feb	NEWA	
		POTASSIUM CITRATE							
		TABLET, EXTENDED RELEASE; ORAL							
		UROCIT-K							
		MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009	Feb	NEWA	
		PRAMIPEXOLE DIHYDROCHLORIDE							
		TABLET; ORAL							
		MIRAPEX							
>D>		BOEHRINGER INGELHEIM	0.75MG	N020667	007	Jul 30, 2007	Mar	CFTG	
>A>	AB		0.75MG	N020667	007	Jul 30, 2007	Mar	CFTG	
>A>		PRAMIPEXOLE DIHYDROCHLORIDE							
>A>	AB	MYLAN	0.75MG	A090764	001	Apr 09, 2010	Mar	NEWA	
		TABLET, EXTENDED RELEASE; ORAL							
		MIRAPEX ER							
		BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Feb	NEWA	
			0.75MG	N022421	002	Feb 19, 2010	Feb	NEWA	
			1.5MG	N022421	003	Feb 19, 2010	Feb	NEWA	
			3MG	N022421	004	Feb 19, 2010	Feb	NEWA	
	+		4.5MG	N022421	005	Feb 19, 2010	Feb	NEWA	
		PRAZOSIN HYDROCHLORIDE							
		CAPSULE; ORAL							
		PRAZOSIN HYDROCHLORIDE							
		@ WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989	Jan	DISC	
		@	EQ 2MG BASE	A072333	001	May 16, 1989	Jan	DISC	
		PREDNISONE							
		TABLET; ORAL							
		PREDNISONE							
	AB	CONTRACT PHARMACAL	5MG	A080209	001		Jan	CAHN	

PREGABALIN

SOLUTION; ORAL
LYRICA
\+ PFIZER 20MG/ML N022488 001 Jan 04, 2010 Jan NEWA

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HYDROCHLORIDE
@ WATSON LABS 1% A080658 001 Jan DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE
@ DURAMED PHARMS BARR EQ 5MG BASE A040207 001 May 01, 1997 Jan DISC
@ EQ 10MG BASE A040207 002 May 01, 1997 Jan DISC
PROCOMP
AB CADISTA PHARMS EQ 5MG BASE A040268 001 Feb 27, 1998 Jan CTNA
AB EQ 10MG BASE A040268 002 Feb 27, 1998 Jan CTNA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HYDROCHLORIDE
@ PAR PHARM 65MG A080269 001 Jan DISC

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
@ CONTRACT PHARMACAL 200MG A083808 001 Jan CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN
>A> SALIX PHARMS 550MG N021361 002 Mar 24, 2010 Mar NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
RISPERDAL CONSTA
\+ ORTHO MCNEIL JANSSEN 25MG/VIAL N021346 001 Oct 29, 2003 Jan CRLD
50MG/VIAL N021346 003 Oct 29, 2003 Jan CRLD

TABLET; ORAL
RISPERIDONE
@ SYNTHON PHARMS 0.25MG A078187 001 Oct 22, 2009 Feb DISC
@ 0.5MG A078187 002 Oct 22, 2009 Feb DISC
@ 1MG A078187 003 Oct 22, 2009 Feb DISC
@ 2MG A078187 004 Oct 22, 2009 Feb DISC
@ 3MG A078187 005 Oct 22, 2009 Feb DISC
@ 4MG A078187 006 Oct 22, 2009 Feb DISC

RITONAVIR

TABLET; ORAL
RITONAVIR
\+ ABBOTT LABS 100MG N022417 001 Feb 10, 2010 Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

AB	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Feb	CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

>A>	AP	BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Mar	CAHN
>A>	AP		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Mar	CAHN
>D>	AP	GENERAMEDIX	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Mar	CAHN
>D>	AP		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>A>	AB	ALEMBIC LTD	EQ 0.25MG BASE	A090429	001	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 0.5MG BASE	A090429	002	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 1MG BASE	A090429	003	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 2MG BASE	A090429	004	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 3MG BASE	A090429	005	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 4MG BASE	A090429	006	Mar 24, 2010	Mar	NEWA
>A>	AB		EQ 5MG BASE	A090429	007	Mar 24, 2010	Mar	NEWA
	AB	GLENMARK GENERICS	EQ 0.25MG BASE	A090135	001	Feb 25, 2010	Feb	NEWA
	AB		EQ 0.5MG BASE	A090135	002	Feb 25, 2010	Feb	NEWA
	AB		EQ 1MG BASE	A090135	003	Feb 25, 2010	Feb	NEWA
	AB		EQ 2MG BASE	A090135	004	Feb 25, 2010	Feb	NEWA
	AB		EQ 3MG BASE	A090135	005	Feb 25, 2010	Feb	NEWA
	AB		EQ 4MG BASE	A090135	006	Feb 25, 2010	Feb	NEWA
	AB		EQ 5MG BASE	A090135	007	Feb 25, 2010	Feb	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	5MG	A074866	001	Nov 26, 1997	Mar	CAHN
>A>	AB	MYLAN	5MG	A074866	001	Nov 26, 1997	Mar	CAHN

SODIUM BICARBONATE

INJECTABLE; INJECTION
SODIUM BICARBONATE

+		HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CRLD

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

>A>		NORDITROPIN FLEXPRO						
>A>	BX	NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Mar	NEWA
>A>	BX		10MG/1.5ML	N021148	009	Mar 01, 2010	Mar	NEWA
>A>			15MG/1.5ML	N021148	010	Mar 01, 2010	Mar	NEWA

STAVUDINE

CAPSULE; ORAL
STAVUDINE

AB	MYLAN	15MG	A079069	001	Dec 29, 2008	Feb	CAHN
AB		20MG	A079069	002	Dec 29, 2008	Feb	CAHN
AB		30MG	A079069	003	Dec 29, 2008	Feb	CAHN

CAPSULE; ORAL
STAVUDINE

AB		MYLAN	40MG	A079069	004	Dec 29, 2008	Feb	CAHN

SUCRALFATE

TABLET; ORAL
SUCRALFATE

>A>	AB	NOSTRUM LABS	1GM	A074415	001	Jun 08, 1998	Mar	CAHN
>D>	AB	RATIOPHARM	1GM	A074415	001	Jun 08, 1998	Mar	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AUROBINDO PHARMA	400MG;80MG	A090624	001	Feb 16, 2010	Jan	NEWA
AB			800MG;160MG	A090624	002	Feb 16, 2010	Jan	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX

AB	+	BOEHRINGER INGELHEIM	0.4MG	N020579	001	Apr 15, 1997	Feb	CFTG

TAMSULOSIN HYDROCHLORIDE

AB		IMPAX LABS	0.4MG	A090377	001	Mar 02, 2010	Feb	NEWA

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE

	+	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		Feb	CRLD

ULTRA-TECHNEKOW FM

	+	MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		Feb	CRLD

TEMOZOLOMIDE

CAPSULE; ORAL
TEMODAR

AB		SCHERING	5MG	N021029	001	Aug 11, 1999	Feb	CFTG
AB			20MG	N021029	002	Aug 11, 1999	Feb	CFTG
AB			100MG	N021029	003	Aug 11, 1999	Feb	CFTG
AB			140MG	N021029	005	Oct 19, 2006	Feb	CFTG
AB			180MG	N021029	006	Oct 19, 2006	Feb	CFTG
AB	+		250MG	N021029	004	Aug 11, 1999	Feb	CFTG

TEMOZOLOMIDE

AB		BARR	5MG	A078879	001	Mar 01, 2010	Feb	NEWA
AB			20MG	A078879	002	Mar 01, 2010	Feb	NEWA
AB			100MG	A078879	003	Mar 01, 2010	Feb	NEWA
AB			140MG	A078879	005	Mar 01, 2010	Feb	NEWA
AB			180MG	A078879	006	Mar 01, 2010	Feb	NEWA
AB			250MG	A078879	004	Mar 01, 2010	Feb	NEWA

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

BX	+	NYCOMED US	0.8%	N021735	001	Oct 01, 2004	Jan	CAHN

THEOPHYLLINE

ELIXIR; ORAL
ELIXOPHYLLIN

>A>	+	CARACO	80MG/15ML	A085186	001		Mar	CAHN

ELIXIR; ORAL
ELIXOPHYLLIN

>D>		+	FOREST LABS	80MG/15ML	A085186	001		Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL
THEOCHRON

>A>	AB		CARACO	100MG	A088320	001	Feb 21, 1985	Mar	CAHN
>A>	AB			200MG	A088321	001	Feb 21, 1985	Mar	CAHN
>A>	AB			300MG	A087400	002	Jan 11, 1983	Mar	CAHN
>D>	AB		INWOOD LABS	100MG	A088320	001	Feb 21, 1985	Mar	CAHN
>D>	AB			200MG	A088321	001	Feb 21, 1985	Mar	CAHN
>D>	AB			300MG	A087400	002	Jan 11, 1983	Mar	CAHN

TINZAPARIN SODIUM

INJECTABLE; INJECTION
INNOHEP

		+	LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000	Feb	CAHN

TOPIRAMATE

TABLET; ORAL
TOPIRAMATE

		@	PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009	Jan	DISC
		@		50MG	A077905	002	Mar 30, 2009	Jan	DISC
		@		100MG	A077905	003	Mar 30, 2009	Jan	DISC
		@		200MG	A077905	004	Mar 30, 2009	Jan	DISC

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE

>D>		@	VICTORY PHARMA	50MG	N021693	001	May 05, 2005	Mar	CMFD
>A>		+		50MG	N021693	001	May 05, 2005	Mar	CMFD

TRANDOLAPRIL

TABLET; ORAL
TRANDOLAPRIL

	AB		EPIC PHARMA	1MG	A078508	003	Jun 18, 2008	Feb	CAHN
	AB			2MG	A078508	001	Jun 18, 2008	Feb	CAHN
	AB			4MG	A078508	002	Jun 18, 2008	Feb	CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

	AB		VINTAGE	50MG	A072192	001	Feb 02, 1989	Feb	CAHN
	AB			100MG	A072193	001	Feb 02, 1989	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
OLEPTRO

			LABOPHARM	150MG	N022411	001	Feb 02, 2010	Feb	NEWA
		+		300MG	N022411	002	Feb 02, 2010	Feb	NEWA

TRETINOIN

CAPSULE; ORAL
TRETINOIN

		+	BARR	10MG	A077684	001	Jun 22, 2007	Feb	CRLD

VESANOID

		@	ROCHE	10MG	N020438	001	Nov 22, 1995	Feb	DISC

CREAM; TOPICAL
TRETINOIN
>A> + TRIAX PHARMS LLC 0.0375% A090098 001 Mar 22, 2010 Mar NEWA

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR
>A> TRELSTAR
>A> + WATSON LABS EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010 Mar NEWA

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
@ SUCAMPO PHARMS 0.15% N021214 001 Aug 03, 2000 Jan DISC

UREA, C-14

CAPSULE; ORAL
PYTEST
+ AVENT 1uCi N020617 001 May 09, 1997 Feb CAHN
PYTEST KIT
+ AVENT 1uCi N020617 002 May 09, 1997 Feb CAHN

URSODIOL

CAPSULE; ORAL
URSODIOL
AB MIKAH PHARMA 300MG A075517 001 Mar 14, 2000 Feb CAHN
AB MYLAN 300MG A090530 001 Feb 17, 2010 Jan NEWA

VALPROATE SODIUM

INJECTABLE; INJECTION
VALPROATE SODIUM
AP HIKMA FARMACEUTICA EQ 100MG BASE/ML A078523 001 Feb 17, 2010 Jan NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE
>A> AP BIONICHE PHARMA USA EQ 500MG BASE/VIAL A065401 001 Jun 30, 2008 Mar CAHN
>A> AP EQ 1GM BASE/VIAL A065401 002 Jun 30, 2008 Mar CAHN
>D> AP GENERAMEDIX EQ 500MG BASE/VIAL A065401 001 Jun 30, 2008 Mar CAHN
>D> AP EQ 1GM BASE/VIAL A065401 002 Jun 30, 2008 Mar CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE
>D> AP GENERAMEDIX 10MG/VIAL A078274 001 Dec 29, 2008 Mar CAHN
>D> AP 20MG/VIAL A078274 002 Dec 29, 2008 Mar CAHN
>A> AP MUSTAFA NEVZAT 10MG/VIAL A078274 001 Dec 29, 2008 Mar CAHN
>A> AP 20MG/VIAL A078274 002 Dec 29, 2008 Mar CAHN

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)
VPRIV
SHIRE HUMAN GENETIC 400 UNITS/VIAL N022575 001 Feb 26, 2010 Feb NEWA
POWDER; IV (INFUSION)
VPRIV
+ SHIRE HUMAN GENETIC 200 UNITS/VIAL N022575 002 Feb 26, 2010 Feb NEWA

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA	EQ 25MG BASE	A090555	001	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 37.5MG BASE	A090555	002	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 50MG BASE	A090555	003	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 75MG BASE	A090555	004	Apr 07, 2010	Mar	NEWA
>A>	AB		EQ 100MG BASE	A090555	005	Apr 07, 2010	Mar	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

>D>		@ PAR PHARM	5MG	A076062	001	Apr 23, 2007	Mar	CAHN
>D>		@	10MG	A076062	002	Apr 23, 2007	Mar	CAHN
>A>		@ WORLD GEN	5MG	A076062	001	Apr 23, 2007	Mar	CAHN
>A>		@	10MG	A076062	002	Apr 23, 2007	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Jan	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Jan	NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010	Jan	NEWA
		10MG	A078780	004	Jan 21, 2010	Jan	NEWA
>A>	TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010	Mar	NEWA
>A>		10MG	A079191	004	Apr 15, 2010	Mar	NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010	Jan	NEWA
		10MG	A078780	002	Jan 21, 2010	Jan	NEWA
>A>	TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010	Mar	NEWA
>A>		10MG	A079191	002	Apr 15, 2010	Mar	NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998	Jan	CAHN
		200MG	A074963	001	Jun 19, 1998	Jan	CAHN

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

+	CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998	Jan	CAHN

TABLET; ORAL

IBUPROFEN

	CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987	Jan	CAHN
		200MG	A071735	001	Sep 10, 1987	Jan	CAHN
		200MG	A072299	001	Jul 01, 1988	Jan	CAHN
		200MG	A073691	001	Feb 25, 1994	Jan	CAHN

PROFEN

	CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986	Jan	CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002	Jan	CAHN

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

	CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993	Jan	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

>D>	@ SCHERING PLOUGH	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CMFD
>A>	+	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CMFD

TABLET, EXTENDED RELEASE; ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

>D>	+	IMPAX LABS	5MG;120MG	A076050	001	Jan 30, 2003	Mar	CRLD
>A>			5MG;120MG	A076050	001	Jan 30, 2003	Mar	CRLD

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 1 COMBINATION PACK

>D>	+	JOHNSON AND JOHNSON	1.2GM,2%	N021308	001	Jun 29, 2001	Mar	CPOT
>A>	+		2%,1.2GM	N021308	001	Jun 29, 2001	Mar	CPOT

CREAM; VAGINAL
MICONAZOLE NITRATE

		PERRIGO R AND D	4%	A091366	001	Jan 15, 2010	Jan	NEWA

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
VISINE-A

	+	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996	Jan	CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 24 HOUR

	+	MCNEIL CONS	240MG	N020021	002	Dec 15, 1992	Feb	CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

		CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2010

NO MARCH 2010 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2010 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE - DIFFERIN						
N022502 001					**>A>** NDF	Mar 17, 2013
ALENDRONATE SODIUM - FOSAMAX						
N021575 001	**>A>** 5994329	Jul 17, 2018		Y		
	>A> 6015801	Jul 17, 2018		Y		
	>A> 6225294	Jul 17, 2018		Y		
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N022217 001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N022217 002					NCE	Mar 05, 2012
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N020965 001					**>A>** M-82	Mar 12, 2013
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
N021303 001	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N021303 006	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N021303 002	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	**>A>** RE41148	Oct 21, 2018	DP			
	>A> RE41148*PED	Apr 21, 2019				
APREPITANT - EMEND						
N021549 001					**>A>** M-82	Mar 19, 2013
APREPITANT - EMEND						
N021549 002					**>A>** M-82	Mar 19, 2013
APREPITANT - EMEND						
N021549 003					**>A>** M-82	Mar 19, 2013
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP						
N021881 001	7658914	Sep 01, 2024	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZTREONAM - CAYSTON						
N050814 001	7208141	Dec 20, 2021	DP U-1031			
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
BALSALAZIDE DISODIUM - COLAZAL						
N020610 001	7452872	Aug 24, 2026	U-141			
	7452872*PED	Feb 24, 2027				
	7625884	Aug 24, 2026	U-141			
	7625884*PED	Feb 24, 2027				
BEXAROTENE - TARGRETIN						
N021055 001	7655699	Apr 22, 2012	DS DP U-509			
BEXAROTENE - TARGRETIN						
N021056 001	7655699	Apr 22, 2012	DS DP U-510			
BIVALIRUDIN - ANGIOMAX						
N020873 001	**>A>** 5196404	May 23, 2010	DS DP U-1040			
	>A> 5196404*PED	Nov 23, 2010				
BUDESONIDE - RHINOCORT						
N020746 001	6686346	Apr 29, 2017	DP U-557	Y		
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699	Y		
	6986904*PED	Oct 29, 2017				
BUDESONIDE - RHINOCORT						
N020746 002	6686346	Apr 29, 2017	DP U-557			
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699			
	6986904*PED	Oct 29, 2017				
BUPROPION HYDROBROMIDE - APLENZIN						
N022108 001	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N022108 002	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N022108 003	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
CAPSAICIN - QUTENZA						
N022395 001					ODE	Nov 16, 2016
CARGLUMIC ACID - CARBAGLU						
N022562 001					**>A>** NCE	Mar 18, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTIBUTEN DIHYDRATE - CEDAX						
N050686 001	5599557	Feb 04, 2014	DP U-578			
	5599557	Feb 04, 2014	DP U-282			
CEFTIBUTEN DIHYDRATE - CEDAX						
N050686 002	5599557	Feb 04, 2014	DP U-578			
	5599557	Feb 04, 2014	DP U-282			
CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA						
N050802 001	RE41134	Feb 24, 2015	DP U-1033			
CLONIDINE HYDROCHLORIDE - JENLOGA						
N022331 001	5869100	Oct 13, 2013	DP			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N022362 001	5607669	Jun 10, 2014	U-757			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-757			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-757			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-493			
	7229613*PED	Oct 17, 2022				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N022362 002	5607669	Jun 10, 2014	U-757			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-757			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-757			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-493			
	7229613*PED	Oct 17, 2022				
DALFAMPRIDINE - AMPYRA						
N022250 001	5370879	Dec 06, 2011	DP		NCE	Jan 22, 2015
	5540938	Jul 30, 2013	U-1030		ODE	Jan 22, 2017
DECITABINE - DACOGEN						
N021790 001					**>A>** D-123	Mar 11, 2013
DICLOFENAC POTASSIUM - CAMBIA						
N022165 001	**>A>** 7482377	May 15, 2017	DS DP U-436		NDF	Jun 17, 2012
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
DOCETAXEL - TAXOTERE						
N020449 001	**>A>** 4814470	May 14, 2010	DS DP		**>A>** I-543	Sep 28, 2010
	>A> 4814470*PED	Nov 14, 2010			**>A>** I-542	Sep 28, 2010
	>A> 5438072	Nov 22, 2013	DP		**>A>** PED	Mar 28, 2011
	>A> 5438072*PED	May 22, 2014				
	>A> 5698582	Jul 03, 2012	DP			
	>A> 5698582*PED	Jan 03, 2013				
	>A> 5714512	Jul 03, 2012	DP			
	>A> 5714512*PED	Jan 03, 2013				
	>A> 5750561	Jul 03, 2012	DP			
	>A> 5750561*PED	Jan 03, 2013				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 001	**>A>** 5502047	Mar 22, 2013	U-620			
	>A> 5585115	Jan 09, 2015	DP			
	>A> 5725884	Sep 30, 2016	DP			
	>A> 5866166	Jun 10, 2016	DP			
	>A> 5948438	Jun 04, 2017	DP			
	>A> 6103219	Dec 17, 2017	DP			
	>A> 6106865	Nov 12, 2019	DP			
	>A> 6211229	Feb 17, 2020	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 002	**>A>** 5502047	Mar 22, 2013	U-620			
	>A> 5585115	Jan 09, 2015	DP			
	>A> 5725884	Sep 30, 2016	DP			
	>A> 5866166	Jun 10, 2016	DP			
	>A> 5948438	Jun 04, 2017	DP			
	>A> 6103219	Dec 17, 2017	DP			
	>A> 6106865	Nov 12, 2019	DP			
	>A> 6211229	Feb 17, 2020	U-620			
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N021427 003	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-795			
	5508276	Jul 18, 2014	DP			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 003	**>A>** 6280959	Oct 30, 2018	DS DP U-930		**>A>** NCE	Nov 20, 2013
	>A> 7160870	Dec 08, 2021	DS DP U-930		**>A>** ODE	Nov 20, 2015
	>A> 7332481	May 24, 2021	U-930			
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7547719	Mar 04, 2024	DS DP U-930			
EPINEPHRINE - ADRENACLICK						
N020800 003	**>A>** 5665071	May 27, 2013	DP			
EPINEPHRINE - ADRENACLICK						
N020800 004	**>A>** 5665071	May 27, 2013	DP			
ESTRADIOL ACETATE - FEMTRACE						
N021633 001	**>A>** 7572779	Mar 02, 2024	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N021633 002	**>A>** 7572779	Mar 02, 2024	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N021633 003	**>A>** 7572779	Mar 02, 2024	U-904			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N021840 001	7615545	Jun 15, 2023	U-1			
EZETIMIBE - ZETIA						
N021445 001	7612058	Jan 25, 2022	U-1027			
	7612058*PED	Jul 25, 2022				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - FENOGLIDE						
N022118 001	7658944	Dec 09, 2024	DP			
FENOFIBRATE - FENOGLIDE						
N022118 002	7658944	Dec 09, 2024	DP			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N020872 001	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
	>A> 7666881	May 18, 2014	U-139			
	>A> 7666881*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N020872 002	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
	>A> 7666881	May 18, 2014	U-139			
	>A> 7666881*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N020872 004	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
	>A> 7666881	May 18, 2014	U-139			
	>A> 7666881*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N021909 001	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR						
N021704 001	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR						
N020786 001	**>A>** 7662835	May 18, 2014	U-139			
	>A> 7662835*PED	Nov 18, 2014				
	>A> 7666881	May 18, 2014	U-139			
	>A> 7666881*PED	Nov 18, 2014				
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 001					**>A>** NPP	Mar 17, 2013
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 002					**>A>** NPP	Mar 17, 2013
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 003					**>A>** NPP	Mar 17, 2013
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 004					**>A>** NPP	Mar 17, 2013
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR						
N020387 001	5608075****	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR						
N020387 002	5608075****	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE							
A077157	001					**>A>** PC	Oct 03, 2010
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE							
A077157	003					**>A>** PC	Oct 03, 2010
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
N021532	002	6878703	Nov 19, 2021	U-3	Y		
HYDROMORPHONE HYDROCHLORIDE - EXALGO							
N021217	001					**>A>** NDF	Mar 01, 2013
HYDROMORPHONE HYDROCHLORIDE - EXALGO							
N021217	002					**>A>** NDF	Mar 01, 2013
HYDROMORPHONE HYDROCHLORIDE - EXALGO							
N021217	003					**>A>** NDF	Mar 01, 2013
IMIQUIMOD - IMIQUIMOD							
A078548	001					PC	Aug 24, 2010
IMIQUIMOD - ZYCLARA							
N022483	001					**>A>** NP	Mar 25, 2013
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N021629	003	6221633	Jun 18, 2018	DS DP U-471			
		6960561	Jan 25, 2023	DP U-471			
		7452860	Mar 22, 2022	DP			
LAMOTRIGINE - LAMICTAL XR							
N022115	001					I-622	Jan 29, 2013
						NDF	May 29, 2012
						PED	Nov 29, 2012
LAMOTRIGINE - LAMICTAL XR							
N022115	002					I-622	Jan 29, 2013
						NDF	May 29, 2012
						PED	Nov 29, 2012
LAMOTRIGINE - LAMICTAL XR							
N022115	003					I-622	Jan 29, 2013
						NDF	May 29, 2012
						PED	Nov 29, 2012
LAMOTRIGINE - LAMICTAL XR							
N022115	004					I-622	Jan 29, 2013
						NDF	May 29, 2012
						PED	Nov 29, 2012
LAPATINIB DITOSYLATE - TYKERB							
N022059	001	**>A>** 6713485	Sep 29, 2020	DS DP U-800		I-620	Jan 29, 2013
LEVETIRACETAM - KEPPRA							
N021872	001					I-563	Mar 19, 2010
						PED	Sep 19, 2010
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N022341	001	6268343	Aug 22, 2017	DS DP U-968		NCE	Jan 25, 2015
		6458924	Aug 22, 2017	DS DP U-968			
		7235627	Aug 22, 2017	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 001	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7674774	Mar 18, 2023	DP U-842			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7678771	Mar 25, 2023	DP U-842			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Apr 08, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 002	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7674774	Mar 18, 2023	DP U-842			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7678771	Mar 25, 2023	DP U-842			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Apr 08, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7674774	Mar 18, 2023	DP U-842			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7678771	Mar 25, 2023	DP U-842			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Apr 08, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7687466	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7674774	Mar 18, 2023	DP U-842			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7678771	Mar 25, 2023	DP U-842			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Apr 08, 2023	DP U-842			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7655630	Feb 24, 2023	DS		**>A>** M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	>A> 7674774	Mar 18, 2023	DP U-842			
	>A> 7678770	Mar 25, 2023	U-842			
	>A> 7678771	Mar 25, 2023	DP U-842			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Apr 08, 2023	DP U-842			
LOSARTAN POTASSIUM - COZAAR						
N020386 001	5608075****	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
LOSARTAN POTASSIUM - COZAAR						
N020386 002	5608075****	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
LOSARTAN POTASSIUM - COZAAR						
N020386 003	5608075****	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
LOSARTAN POTASSIUM - LOSARTAN POTASSIUM						
A076958 001					**>A>** PC	Oct 03, 2010
LOSARTAN POTASSIUM - LOSARTAN POTASSIUM						
A076958 002					**>A>** PC	Oct 06, 2010
LOSARTAN POTASSIUM - LOSARTAN POTASSIUM						
A076958 003					**>A>** PC	Oct 03, 2010
MESALAMINE - SFROWASA						
N019618 002	7645801	Jul 24, 2027	DS DP			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N022044 001	**>A>** 6890898	Feb 02, 2019	U-803			
	>A> 6890898	Feb 02, 2019	U-1038			
	>A> 6890898	Feb 02, 2019	U-1036			
	>A> 7078381	Feb 02, 2019	U-803			
	>A> 7078381	Feb 02, 2019	U-1038			
	>A> 7078381	Feb 02, 2019	U-1036			
	>A> 7125873	Jul 26, 2022	DP U-803			
	>A> 7125873	Jul 26, 2022	DP U-1038			
	>A> 7125873	Jul 26, 2022	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N022044 002	**>A>** 6890898	Feb 02, 2019	U-803			
	>A> 6890898	Feb 02, 2019	U-1038			
	>A> 6890898	Feb 02, 2019	U-1036			
	>A> 7078381	Feb 02, 2019	U-803			
	>A> 7078381	Feb 02, 2019	U-1038			
	>A> 7078381	Feb 02, 2019	U-1036			
	>A> 7125873	Jul 26, 2022	DP U-803			
	>A> 7125873	Jul 26, 2022	DP U-1038			
	>A> 7125873	Jul 26, 2022	DP U-1036			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N021419 001	**>A>** 7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N021419 002	**>A>** 7691880	Oct 07, 2024	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 001	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 002	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 003	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 004	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 005	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 006	**>A>** 7682633	Jun 19, 2027			U-443	
	>A> 7682634	Jun 19, 2027	DP			
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX						
N021598 001	**>A>** 7671070	Sep 29, 2019			U-709	
	>A> 7671070*PED	Mar 29, 2020				
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N019734 004	7659291	Apr 18, 2027			U-1029	
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N019734 003	7659291	Apr 18, 2027			U-1029	
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER						
N019734 002	7659291	Apr 18, 2027			U-1029	
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER						
N019734 005	7659291	Apr 18, 2027			U-1029	
OLMESARTAN MEDOXOMIL - BENICAR						
N021286 001					NPP	Feb 04, 2013
					PED	Aug 04, 2010
OLMESARTAN MEDOXOMIL - BENICAR						
N021286 003					NPP	Feb 04, 2013
					PED	Aug 04, 2010
OLMESARTAN MEDOXOMIL - BENICAR						
N021286 004					NPP	Feb 04, 2013
					PED	Aug 04, 2010
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001					M-90	Feb 22, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002					M-90	Feb 22, 2013
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003					M-90	Feb 22, 2010
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001					M-90	Feb 22, 2013
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 001	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 002	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 003	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 004	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 005	**>A>** 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 006	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 007	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N020553 008	**>A>** 7674799	Mar 30, 2025	DS			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 001	**>A>** 7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 002	**>A>** 7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 003	**>A>** 7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 004	**>A>** 7276250	Feb 04, 2023	DP U-826			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 005	**>A>** 7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 006	**>A>** 7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N021610 007	**>A>** 7276250	Feb 04, 2023	DP U-826			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 001	7658918	Feb 20, 2028	DP			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 002	7658918	Feb 20, 2028	DP			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 003	7658918	Feb 20, 2028	DP			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 004	7658918	Feb 20, 2028	DP			
PANTOPRAZOLE SODIUM - PROTONIX						
N022020 001	7544370	Jun 07, 2026	DP			
	7544370*PED	Dec 07, 2026				
PENCICLOVIR SODIUM - DENAVIR						
N020629 001	**>A>** 5866581	Oct 04, 2014	U-501			
	>A> 6124304	Oct 04, 2014	U-501			
POLIDOCANOL - ASCLERA						
N021201 001					**>A>** NCE	Mar 30, 2015
POLIDOCANOL - ASCLERA						
N021201 002					**>A>** NCE	Mar 30, 2015
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 001	4886812	Oct 08, 2010	DS DP		**>A>** I-623	Mar 19, 2013
	>A> 7695734	Apr 26, 2028	DP		**>A>** NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 002	4886812	Oct 08, 2010	DS DP		**>A>** I-623	Mar 19, 2013
	>A> 7695734	Apr 26, 2028	DP		**>A>** NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 003	4886812	Oct 08, 2010	DS DP		**>A>** I-623	Mar 19, 2013
	>A> 7695734	Apr 26, 2028	DP		**>A>** NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 004	4886812	Oct 08, 2010	DS DP		**>A>** I-623	Mar 19, 2013
	>A> 7695734	Apr 26, 2028	DP		**>A>** NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 005	4886812	Oct 08, 2010	DS DP		**>A>** I-623	Mar 19, 2013
	>A> 7695734	Apr 26, 2028	DP		**>A>** NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE						
A077724 001					PC	Jul 03, 2010
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE						
A077724 002					PC	Jul 03, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE							
A077724	003					PC	Jul 03, 2010
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE							
A077724	004					PC	Jul 03, 2010
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE							
A077724	005					PC	Jul 03, 2010
PREGABALIN - LYRICA							
N022488	001	5563175	Oct 08, 2013	U-661		I-535	Jun 21, 2010
		6001876	Dec 30, 2018	U-819			
		6001876	Dec 30, 2018	U-55			
		6197819	Dec 30, 2018	DS DP			
REGADENOSON - LEXISCAN							
N022161	001	7655636	Jun 22, 2019	U-869			
		7655637	Jun 22, 2019	DS DP U-869			
RIFAXIMIN - XIFAXAN							
N021361	002	>A> 7045620	Jun 19, 2024	DS		>A> NP	Mar 24, 2013
RITONAVIR - RITONAVIR							
N022417	001	5541206	Jul 30, 2013	DS DP U-688			
		5541206*PED	Jan 30, 2014				
		5635523	Jun 03, 2014	U-688			
		5635523*PED	Dec 03, 2014				
		5648497	Jul 15, 2014	DS			
		5648497*PED	Jan 15, 2015				
		5674882	Oct 07, 2014	U-688			
		5674882*PED	Apr 07, 2015				
		6037157	Jun 26, 2016	U-688			
		6037157*PED	Dec 26, 2016				
		6703403	Jun 26, 2016	U-688			
		6703403*PED	Dec 26, 2016				
		7148359	Jul 19, 2019	DP			
		7148359*PED	Jan 19, 2020				
		7364752	Nov 10, 2020	DP U-688			
		7364752*PED	May 10, 2021				
ROMIDEPSIN - ISTODAX							
N022393	001					ODE	Nov 05, 2016
ROSUVASTATIN CALCIUM - CRESTOR							
N021366	002	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
ROSUVASTATIN CALCIUM - CRESTOR							
N021366	003	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
ROSUVASTATIN CALCIUM - CRESTOR							
N021366	004	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
ROSUVASTATIN CALCIUM - CRESTOR							
N021366	005	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SITAGLIPTIN PHOSPHATE - JANUVIA						
N021995 001	**>A>** 6890898	Feb 02, 2019	U-775			
	>A> 6890898	Feb 02, 2019	U-1039			
	>A> 6890898	Feb 02, 2019	U-1036			
	>A> 7078381	Feb 02, 2019	U-775			
	>A> 7078381	Feb 02, 2019	U-1038			
	>A> 7078381	Feb 02, 2019	U-1037			
	>A> 7078381	Feb 02, 2019	U-1036			
	>A> 7125873	Jul 26, 2022	U-775			
	>A> 7125873	Jul 26, 2022	U-1038			
	>A> 7125873	Jul 26, 2022	U-1037			
	>A> 7125873	Jul 26, 2022	U-1036			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N021995 002	**>A>** 6890898	Feb 02, 2019	U-775			
	>A> 6890898	Feb 02, 2019	U-1039			
	>A> 6890898	Feb 02, 2019	U-1036			
	>A> 7078381	Feb 02, 2019	U-775			
	>A> 7078381	Feb 02, 2019	U-1038			
	>A> 7078381	Feb 02, 2019	U-1037			
	>A> 7078381	Feb 02, 2019	U-1036			
	>A> 7125873	Jul 26, 2022	U-775			
	>A> 7125873	Jul 26, 2022	U-1038			
	>A> 7125873	Jul 26, 2022	U-1037			
	>A> 7125873	Jul 26, 2022	U-1036			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N021995 003	**>A>** 6890898	Feb 02, 2019	U-775			
	>A> 6890898	Feb 02, 2019	U-1039			
	>A> 6890898	Feb 02, 2019	U-1036			
	>A> 7078381	Feb 02, 2019	U-775			
	>A> 7078381	Feb 02, 2019	U-1038			
	>A> 7078381	Feb 02, 2019	U-1037			
	>A> 7078381	Feb 02, 2019	U-1036			
	>A> 7125873	Jul 26, 2022	U-775			
	>A> 7125873	Jul 26, 2022	U-1038			
	>A> 7125873	Jul 26, 2022	U-1037			
	>A> 7125873	Jul 26, 2022	U-1036			
SODIUM OXYBATE - XYREM						
N021196 001	7668730	Mar 07, 2024	U-1028			
SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N021892 001	**>A>** 7687075	Jun 22, 2028	DS DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N021148 008	**>A>** 5849700	Dec 15, 2015	U-1041		**>A>** I-572	Oct 31, 2011
	>A> 5849704	Dec 15, 2015	DP U-1041		**>A>** I-551	Sep 20, 2010
					>A> I-536	May 31, 2010
					>A> ODE	May 31, 2014
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N021148 009	**>A>** 5849700	Dec 15, 2015	U-1041		**>A>** I-572	Oct 31, 2011
	>A> 5849704	Dec 15, 2015	DP U-1041		**>A>** I-551	Sep 20, 2010
					>A> I-536	May 31, 2010
					>A> ODE	May 31, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N021148 010	**>A>** 5849700	Dec 15, 2015	U-1041		**>A>** I-572	Oct 31, 2011
	>A> 5849704	Dec 15, 2015	DP U-1041		**>A>** I-551	Sep 20, 2010
					>A> I-536	May 31, 2010
					>A> ODE	May 31, 2014
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001					**>A>** NPP	Mar 24, 2013
TERBINAFINE - LAMISIL AT						
N021958 001	**>A>** 5681849	Oct 28, 2014	DP			
	>A> 5681849*PED	Apr 28, 2015				
	>A> 5856355	May 18, 2012	DP U-540			
	>A> 5856355	May 18, 2012	DP U-504			
	>A> 5856355*PED	Nov 18, 2012				
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA						
N021395 001	7642268	Sep 24, 2021	DS DP			
TOLTERODINE TARTRATE - DETROL						
N020771 001	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
TOLTERODINE TARTRATE - DETROL						
N020771 002	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 001	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 002	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
TRIPTORELIN PAMOATE - TRELSTAR						
N022437 001	**>A>** 5776885	Jul 07, 2015	DP		**>A>** NP	Mar 10, 2013
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 001	**>A>** 7696206	Oct 31, 2018	DS DP U-533			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 002	**>A>** 7696206	Oct 31, 2018	DS DP U-533			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 003	**>A>** 7696206	Oct 31, 2018	DS DP U-533			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 004	**>A>** 7696206	Oct 31, 2018	DS DP U-533			
VARENICLINE TARTRATE - CHANTIX						
N021928 001	**>A>** 7265119	Aug 03, 2022	DS DP U-56			
VARENICLINE TARTRATE - CHANTIX						
N021928 002	**>A>** 7265119	Aug 03, 2022	DS DP U-56			
VELAGLUCERASE ALFA - VPRIV						
N022575 001					NCE	Feb 26, 2015
VELAGLUCERASE ALFA - VPRIV						
N022575 002					NCE	Feb 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORINOSTAT - ZOLINZA						
N021991 001	7652069	Mar 04, 2023	DS			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm